202 related articles for article (PubMed ID: 16787344)
21. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
Nucl Med Biol; 1996 Aug; 23(6):851-6. PubMed ID: 8940730
[TBL] [Abstract][Full Text] [Related]
23. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
25. Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine.
Roa WH; Miller GG; McEwan AJ; McQuarrie SA; Tse J; Wu J; Wiebe LI
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):425-32. PubMed ID: 9607361
[TBL] [Abstract][Full Text] [Related]
26. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
[TBL] [Abstract][Full Text] [Related]
27. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy.
Boyd M; Mairs SC; Stevenson K; Livingstone A; Clark AM; Ross SC; Mairs RJ
J Gene Med; 2002; 4(5):567-76. PubMed ID: 12221650
[TBL] [Abstract][Full Text] [Related]
28. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770
[TBL] [Abstract][Full Text] [Related]
30. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
31. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma.
Cunningham S; Boyd M; Brown MM; Carlin S; McCluskey A; Livingstone A; Mairs RJ; Wheldon TE
Med Pediatr Oncol; 2000 Dec; 35(6):708-11. PubMed ID: 11107152
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy using alpha emitters.
Vaidyanathan G; Zalutsky MR
Phys Med Biol; 1996 Oct; 41(10):1915-31. PubMed ID: 8912371
[TBL] [Abstract][Full Text] [Related]
33. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
34. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
35. Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.
Zhao Y; Zhong X; Ou X; Cai H; Wu X; Huang R
Front Med; 2017 Mar; 11(1):120-128. PubMed ID: 28213878
[TBL] [Abstract][Full Text] [Related]
36. Organic cation transporter 3 mediates the non-norepinephrine transporter driven uptake of meta-[
Ohshima Y; Sasaki I; Watanabe S; Sakashita T; Higashi T; Ishioka NS
Nucl Med Biol; 2022; 112-113():44-51. PubMed ID: 35802985
[TBL] [Abstract][Full Text] [Related]
37. No-carrier-added 123I-MIBG: an initial clinical study in patients with phaeochromocytoma.
Owens J; Bolster AA; Prosser JE; Cunningham S; Mairs RJ; Neilly JB; Reed NS; Hilditch TE
Nucl Med Commun; 2000 May; 21(5):437-40. PubMed ID: 10874700
[TBL] [Abstract][Full Text] [Related]
38. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
39. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma.
Altmann A; Kissel M; Zitzmann S; Kübler W; Mahmut M; Peschke P; Haberkorn U
J Nucl Med; 2003 Jun; 44(6):973-80. PubMed ID: 12791828
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
